Wolfram Resources Plc (LSE: WFR, ticker reference: MIO), a Main Market-listed special purpose acquisition company, announced on 18 November 2026 that it has signed a non-binding Memorandum of Understanding to acquire the entire issued share capital of Ellipses Pharma Limited, a London-based clinical-stage oncology drug development company. The proposed transaction, which follows an earlier announcement on 16 November 2026, would see Wolfram relist on the Main Market under the Equity Shares (Commercial Companies) category. Completion is targeted for early 2027, subject to due diligence, FCA approval, and shareholder consent.
Key Points
- Wolfram Resources Plc (LSE: WFR, reference: MIO) — Main Market shell company proposing a transformative acquisition
- Non-binding MoU signed to acquire 100% of Ellipses Pharma Limited, a London-headquartered oncology drug developer founded in 2017
- Consideration expected in new Wolfram ordinary shares; a fundraise is also planned alongside the proposed relisting
- Investors should watch for due diligence outcomes, FCA prospectus approval, and shareholder vote expected ahead of early 2027 completion target
Wolfram Resources Proposes to Bring Ellipses Pharma's Clinical Oncology Portfolio to the London Main Market
Wolfram Resources currently operates as a special purpose acquisition company, with its ordinary shares traded in the Equity Shares (Shell Companies) listing category on the London Stock Exchange's Main Market. The proposed acquisition of Ellipses Pharma would transition the enlarged group into the Equity Shares (Commercial Companies) category. Ellipses Pharma, founded in 2017 by Professor Sir Chris Evans OBE, focuses exclusively on oncology and sources candidate assets globally, selecting them through an independent Scientific Advisory Group comprising more than 300 leading oncology experts across multiple tumour types and therapeutic modalities. The announcement states that consideration is expected to be satisfied entirely in new Wolfram ordinary shares, with final terms subject to due diligence.
Ellipses Pharma's Pipeline Includes Phase 2 Programmes in Lung Cancer and Breast Cancer Across Three Continents
Ellipses Pharma's clinical portfolio spans trial sites across the United States, Europe, and Asia Pacific. Its pipeline includes EP0031, known as lunbotinib, a next-generation selective RET inhibitor currently in Phase 2 development for RET-altered non-small cell lung cancer, partnered with Kelun-Biotech. It also includes EP0062, known as vosilasarm, an oral selective androgen receptor modulator in Phase 2 development for ER+/HER2- breast cancer. The company did not disclose financial metrics or revenue figures in the announcement. The breadth of the clinical pipeline and its international trial footprint represent key assets Wolfram shareholders would gain exposure to if the proposed transaction completes.
Berenberg Appointed as Sponsor While Transaction Remains Subject to Multiple Regulatory and Shareholder Conditions
Wolfram has appointed Joh. Berenberg, Gossler & Co. KG, London Branch, as Sponsor and Financial Adviser for the proposed transaction, with AlbR Capital Limited acting as corporate broker. The transaction faces several conditions before completion, including satisfactory due diligence, FCA approval of a prospectus, shareholder approval, and a Rule 9 Waiver from the Panel on Takeovers and Mergers. The announcement explicitly cautions that commercial terms have not yet been agreed and that shareholders should not place undue reliance on the MoU. Detailed technical, financial, and legal due diligence commenced immediately following the announcement, with completion of the full proposed transaction targeted for early 2027.



Please wait processing your request...